Fill out the form to download your copy and see the results.

Use of Digital Assessments to Measure Visual and Auditory Biomarkers of Alzheimer’s Disease

 

In this poster you will learn: 

  • Development of novel treatments for Alzheimer’s Disease (AD) requires accurate measurement of symptom severity for patient selection and assessment of treatment response
  • AD trials to-date in mild to moderate patients and those with MCI have relied on measures of cognition for patient selection and measurement of change over time
  • Traditional assessments of AD limit scalability in clinical trials as they are burdensome for patients, caretakers, and clinicians, and can lead to subjective measurements
  • As the field moves toward interventions in earlier stages of disease and prodromal patients, reliable and scalable methods to objectively measure changes are critical for patient selection and assessment of treatment efficacy